Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Nanus

Showing results (111-120 of 168) with videos related to

Pageof 17
Sort By:
European Urology|February 8, 2016
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate CancerScott T Tagawa, Edwin M Posadas, Justine Bruce, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2019
Clinical features of neuroendocrine prostate cancerVincenza Conteduca, Clara Oromendia, Kenneth W Eng, et al.
Nature Genetics|November 8, 2016
Clonal evolution of chemotherapy-resistant urothelial carcinomaBishoy M Faltas, Davide Prandi, Scott T Tagawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate CancerHimisha Beltran, Adam Jendrisak, Mark Landers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trialMaha H A Hussain, Gary R MacVicar, Daniel P Petrylak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2024
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or EnzalutamideSusan Halabi, Siyuan Guo, Joseph J Park, et al.
Cancer Research|July 30, 2011
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancerMedha S Darshan, Matthew S Loftus, Maria Thadani-Mulero, et al.
Urologic Oncology|July 1, 2020
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup>Lu-J591) for metastatic castration-resistant prostate cancerJaspreet S Batra, Muhammad Junaid Niaz, Young E Whang, et al.
Plos One|January 4, 2014
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flowGunjan Gakhar, Vicente N Navarro, Madelyn Jurish, et al.
AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science|July 2, 2019
Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed ConsentCindy Chen, Scott P Turner, Evan T Sholle, et al.
Pageof 17

Showing results (111-120 of 168) with videos related to

Sort By:
Pageof 17
European Urology|February 8, 2016
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate CancerScott T Tagawa, Edwin M Posadas, Justine Bruce, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2019
Clinical features of neuroendocrine prostate cancerVincenza Conteduca, Clara Oromendia, Kenneth W Eng, et al.
Nature Genetics|November 8, 2016
Clonal evolution of chemotherapy-resistant urothelial carcinomaBishoy M Faltas, Davide Prandi, Scott T Tagawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate CancerHimisha Beltran, Adam Jendrisak, Mark Landers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trialMaha H A Hussain, Gary R MacVicar, Daniel P Petrylak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2024
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or EnzalutamideSusan Halabi, Siyuan Guo, Joseph J Park, et al.
Cancer Research|July 30, 2011
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancerMedha S Darshan, Matthew S Loftus, Maria Thadani-Mulero, et al.
Urologic Oncology|July 1, 2020
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup>Lu-J591) for metastatic castration-resistant prostate cancerJaspreet S Batra, Muhammad Junaid Niaz, Young E Whang, et al.
Plos One|January 4, 2014
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flowGunjan Gakhar, Vicente N Navarro, Madelyn Jurish, et al.
AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science|July 2, 2019
Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed ConsentCindy Chen, Scott P Turner, Evan T Sholle, et al.
Pageof 17